Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
about
The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancerAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisMate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials.Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysisEfficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registryOxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort studyAngiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survivalBevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabLeveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational researchChemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort studySpecial AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer.Toxicity of bevacizumab in combination with chemotherapy in older patientsPhase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapyTrends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximabDynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.Bevacizumab: a review of its use in advanced cancer.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland.Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.A comparison of the effects of medical Qigong and standard exercise therapy on symptoms and quality of life in patients with advanced cancer.Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway.Survival after recurrence of stage I-III breast, colorectal, or lung cancer.The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.A prognostic indicator of survival in metastatic colorectal cancer patients in the era of molecular-targeted agents: the modified Glasgow Prognostic Score.The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.
P2860
Q27011366-5EAE72D8-00E5-4B6B-ACE4-F592D91C4DC2Q28534015-B41C2939-44AA-4850-84C9-01F709ADE4F5Q31092851-ECA4A92C-DC07-4020-A4A4-0DA6FD0A1E8EQ33602255-508265BA-71B5-4631-B19A-E487DF4D5387Q33648921-DE594689-8067-4BFC-939D-83B6B1D8DF6BQ33904867-12C00208-8AC3-48B2-B5D8-C7655FAAFFCDQ34005111-7B08C9CC-4655-4BCD-BBA1-C783B2C36056Q34649050-F5ED684B-36E5-4D86-8303-0E91D3541A40Q34773758-E336C01A-5703-4457-A73F-9E2479B62E4EQ34899949-D40986C5-C0C3-4EDF-83AF-F04EE69A7E06Q35048299-09AB5B67-9F71-4264-86D7-759325810EAEQ35130633-7C5D18BC-30F1-4940-B9F5-C69AA84DC48BQ35535424-5C64B2F2-EB1D-4217-A580-FDB57A1CA6CAQ35783911-F1C5BC46-9F83-4F97-8C93-05459F2D9A3AQ35925226-76D2D3BD-9FA3-4600-B954-4C9EDA80975CQ36301449-FB0FD719-05F0-4D59-8A94-D5DE09FCFDC0Q36535678-51609F6D-7B42-4652-B7D8-5BCDE3915384Q36542468-DCCFDD29-CB32-4AB8-AA03-0A0ADE443C08Q36783174-82A63AC9-5B94-4AB5-AFF4-005F9AEF6478Q36804502-2F70DF6D-3B1F-4023-A2E7-0E0BC9B33FA1Q36804867-B81BC3F4-08F2-42D3-87A0-4666746549F8Q36862836-61962BDC-DB44-47F1-8A04-3085D9AFB829Q36942426-53CDAF97-F966-4312-A6C7-125D2852BDE9Q37146157-ACD473F0-7B52-457B-BD48-85EEB53557D0Q37367448-0F1CADB6-D37E-47F9-BDE8-93FE1A2DE79CQ37978979-6738E008-C6D1-45A5-A5F1-4353EDEEDEC9Q38217738-955867FD-9301-4B4C-A3C7-68500C119961Q38260176-917B608E-6563-4277-8CE0-B50A9FF11449Q38307997-ABCA4DB9-2FEC-470D-8696-B19A5072FFC4Q38525475-E2415A13-6200-486F-B588-72EA53F79702Q38814615-B22BB6BE-ECCA-4D1B-9204-7915B49E50F8Q39583831-047CA4C7-4257-4112-B335-9BC41404F187Q39996371-279B9367-5A7A-44CA-8F22-B0ACA91FAFAEQ47588229-6B989FC1-D28B-42E8-ACED-2A9990736E7EQ47969105-A5545CC5-59BC-49A4-B06E-8B6735066A6EQ49379642-7D906A8A-6C6A-4B71-8ADA-F48F948BF152Q50528546-97B46CC8-F426-4A14-A446-E1017DB3010FQ54312897-51BFC1A2-76AC-4B7B-97AC-46292AD100B1Q54415533-4D1D1DB8-E9FC-4B12-BE0A-E37C826E402AQ55005151-32AA15B8-547D-4A15-AF0F-E0C83F0C4DB9
P2860
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@ast
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@en
type
label
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@ast
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@en
prefLabel
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@ast
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@en
P2093
P2860
P921
P356
P1476
Effectiveness of bevacizumab w ...... th stage IV colorectal cancer.
@en
P2093
Deborah Schrag
Hanna K Sanoff
William Carpenter
P2860
P304
P356
10.1200/JCO.2011.38.9650
P407
P577
2012-01-17T00:00:00Z